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Developing B cells undergo a series of highly 
ordered maturation steps that result in the ex-
pression of a mature form of the BCR on the cell 
surface. Expression of a mature BCR first occurs 
at the immature B cell stage, and approximately 
half of these newly generated receptors have been 
shown to react with self-antigens (Grandien et al., 
1994; Casellas et al., 2001; Wardemann et al., 
2003). Normally, cells expressing a BCR that 
recognizes  self-antigens  are  negatively  selected 
and prevented from entering the mature periph-
eral B cell compartment (Pelanda et al., 1997; 
Halverson et al., 2004). In contrast, cells that ex-
press nonautoreactive BCRs enter the peripheral 
circulation and migrate to the spleen, where they 
undergo further differentiation (Pelanda et al., 
1997; Halverson et al., 2004). Therefore, the dif-
ferentiation step of immature B cells into transi-
tional B cells is important for the generation of 
the primary naive B cell repertoire.
It is well documented that engagement of 
antigen by the BCR activates a signaling cascade 
that mediates antigen-specific responses. Studies 
conducted over the past decade have indicated 
that the BCR is also capable of signaling in the 
absence of antigen binding (Monroe, 2006). This 
ligand-independent, or tonic, BCR signal has 
been reported to be involved in regulating 
peripheral B cell survival as well as early B cell 
development. Specifically, gene ablation studies 
showed that deletion of the BCR leads to a 
dramatic loss of transitional and mature B cells 
in the spleen, and that this loss can be delayed by 
constitutive Bcl-2 expression (Lam et al., 1997). 
Subsequently, it was determined that the sig-
naling capacity of the BCR, and not solely its 
expression, is critical for the maintenance of pe-
ripheral B cells (Meffre and Nussenzweig, 2002; 
Kraus et al., 2004). Specific to B cell develop-
ment, it was reported that when tonic BCR sig-
naling is interrupted through either the use of 
chemical inhibitors or inducible gene deletion, 
immature B cells undergo a developmental 
regression and express a gene profile similar to 
that of pro– and pre–B cells, and have reduced 
transcription of genes encoding mature B cell 
markers (Tze et al., 2005).
The specific signaling components of the 
tonic and antigen-mediated BCR pathways 
have yet to be fully elucidated, and whether 
these pathways are only quantitatively or also 
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B cell receptors (BCRs) generate tonic signals critical for B cell survival and early B cell 
development. To determine whether these signals also mediate the development of transi-
tional and mature B cells, we examined B cell development using a mouse strain in which 
nonautoreactive immunoglobulin heavy and light chain–targeted B cells express low surface 
BCR levels. We found that reduced BCR expression translated into diminished tonic BCR 
signals that strongly impaired the development of transitional and mature B cells. Constitu-
tive expression of Bcl-2 did not rescue the differentiation of BCR-low B cells, suggesting 
that this defect was not related to decreased cell survival. In contrast, activation of the Ras 
pathway rescued the differentiation of BCR-low immature B cells both in vitro and in vivo, 
whereas extracellular signal-regulated kinase (Erk) inhibition impaired the differentiation 
of normal immature B cells. These results strongly suggest that tonic BCR signaling medi-
ates the differentiation of immature into transitional and mature B cells via activation of 
Erk, likely through a pathway requiring Ras.
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bution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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nonautoreactive and hypomorphic for Ig-. The experiments 
reported in this paper were performed on 3-83Igi-low mice, 
and most were repeated on B1-8Hi/3-83ki-low animals to con-
firm that the results were independent of antibody specificity.
Total bone marrow cells from 3-83Igi and 3-83Igi-low 
mice were cultured in IL-7 for 4 d to enrich for B cells, and 
total cell lysates from the cultured cells were analyzed by 
Western blotting to quantify Ig- and actin (Fig. 1 B). Band 
intensities for Ig- were normalized to those of actin, and the 
normalized Ig- levels of 3-83Igi cells were set to 100%. These 
analyses found that Ig- levels in 3-83Igi-low bone marrow B 
cells were 12% (12.4 ± 6.4%; n = 3) of those in 3-83Igi 
cells. The hypomorphic expression of Ig- in 3-83Igi-low B 
cells resulted in comparably reduced expression of surface 
IgM (Fig. 1 C), which was 18% (as calculated from the ra-
tio of mean fluorescence intensities [MFIs] that follow) of the 
normal level on immature B cells on average, and was main-
tained at a similar level throughout B cell development (not 
depicted). The degree to which IgM expression was reduced 
was calculated by comparing the MFIs of surface IgM expres-
sion on 3-83Igi (179.4 ± 47.3; n = 5) and 3-83Igi-low (32.9 ± 
7.8; n = 5) bone marrow B220+IgM+IgD– immature B 
cells. In similar analyses, IgD expression was found to be 40% 
of normal levels on 3-83Igi-low transitional B cells (3-83Igi: 
28.6 ± 3.7 [n = 3]; 3-83Igi-low: 12 ± 2.7 [n = 3]) and reached 
70% of normal levels on mature B cells (3-83Igi: 114.6 ± 2.5 
[n = 3]; 3-83Igi-low: 83.5 ± 12.5 [n = 3]) in the spleen (un-
published data). IgD has been suggested to possess higher 
affinity for Ig-/ than IgM (Schamel and Reth, 2000), po-
tentially explaining the differential effect of hypomorphic Ig- 
on their expression. Nevertheless, low Ig- expression trans-
lated into low BCR expression at every B cell stage. It is im-
portant to note that despite the reduced level of surface BCR, 
the large majority of the peripheral B220+IgM+ B cells in   
3-83Igi-low (94.1 ± 3.2% 3-83Ig+ cells; n = 4) and B1-8Hi/ 
3-83ki-low (95.3 ± 3.5% B1-8H3-83+ cells; n = 6) mice 
retained the original specificity, indicating minimal receptor 
editing during B cell development (unpublished data).
BCR-low mice manifest reduced numbers of transitional  
and mature B cells
Initial characterization of 3-83Igi-low mice revealed signifi-
cantly reduced numbers of B cells in late stages of bone mar-
row development and in all B cell subsets in the spleen (Fig. 1, 
D–F). Although numbers of bone marrow immature B cells 
were comparable in 3-83Igi and 3-83Igi-low mice (Fig. 1 E), 
numbers of transitional and mature B cells in both bone 
marrow and spleen were reduced two- to fourfold (Fig. 1,   
E and F). Similar differences in transitional and peripheral 
mature B cell numbers were observed in B1-8Hi/3-83ki-low 
mice when compared with B1-8Hi/3-83ki control animals 
(Fig. S1), as well as in mb1-low mice carrying a normal Ig 
repertoire, for the B cell populations analyzed (Fig. S2). These 
findings indicate that a threshold level of BCR expression is 
required for the differentiation of immature into transitional 
B cells, and potentially also of transitional into mature B cells, 
qualitatively distinct is still under investigation. Ablation of 
BCR genes has been useful for recognizing the existence of 
tonic BCR signaling, but because this leads to cell death it has 
not allowed the analysis of the nature of tonic BCR signaling 
and its role in B cell development. To bypass this issue, we 
used a novel mouse strain that carries two differentially tar-
geted alleles of the mb-1 gene, resulting in hypomorphic ex-
pression of the wild-type form of Ig-. In these mice, reduced 
expression of Ig- translates into comparably reduced expres-
sion of the BCR that manifests as reduced tonic BCR signal-
ing. In this study, we used BCR-low mice to investigate 
whether tonic BCR signaling is required for the selection of 
nonautoreactive immature B cells from the bone marrow into 
the peripheral lymphoid system and for their differentiation 
into transitional and mature peripheral B cells.
Our study shows that nonautoreactive immature B cells 
with low surface BCR expression are capable of, but ineffi-
cient at, reaching the peripheral B cell compartment and dif-
ferentiating into transitional and mature B cells. Furthermore, 
we show that reduced numbers of transitional and mature   
B cells in BCR-low mice is primarily caused by a defect in the 
differentiation capacity of immature B cells rather than re-
duced cell survival. Finally, we show that the differentiation of 
normal immature B cells requires the activation of extracellular 
signal-regulated kinase (Erk), and that the impaired differenti-
ation of BCR-low immature B cells can be rescued by activat-
ing the Ras pathway, via an Erk-dependent mechanism.
RESULTS
Generation of nonautoreactive BCR-low mice
Ig- associates with Ig- and the H and L chains to form the 
BCR, and all protein subunits are absolutely required for sur-
face receptor expression (Hombach et al., 1990). Therefore, 
low Ig- levels can result in reduced BCR expression and, 
presumably, in low BCR signaling. We previously generated 
conditional mb-1 mice in which a cDNA cassette encoding 
wild-type exons II–V replaced the equivalent genomic exons 
(Pelanda et al., 2002a,b). Although the targeted allele expressed 
a wild-type form of Ig-, the expression level was reduced 
relative to that of the genomic allele. The reason for this dif-
ference is presently unknown but likely involves the disrup-
tion of a transcription regulatory element within the targeted 
allele. Conditional mb-1 mice were bred to Ig-–deficient 
(mb-1 null) mice (Pelanda et al., 2002a,b) to generate hemi-
zygous animals named mb1-low (Fig. 1 A). To study the role 
and nature of tonic BCR signaling in the differentiation of 
nonautoreactive immature B cells, we bred mb1-low mice 
to 3-83Igi,H-2d (Pelanda et al., 1997; Braun et al., 2000; 
Halverson et al., 2004) and B1-8Hi/3-83ki (Pelanda et al., 1997) 
H and L chain gene–targeted mice to generate 3-83Igi-low 
and B1-8Hi/3-83ki-low mice, respectively. It has been well 
established that both the 3-83H/3-83– and B1-8H/3-83–
expressing B cells are nonautoreactive on an H-2d genetic back-
ground (Nemazee and Bürki, 1989; Lang et al., 1996; Pelanda 
et al., 1997; Novobrantseva et al., 2005). Therefore, B cells 
from  both  3-83Igi-low  and  B1-8Hi/3-83ki-low  mice  are JEM VOL. 207, March 15, 2010 
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the cells progressed from the immature to the transitional and 
mature B cell stages, indicating an impaired ability of 3-83Igi-low 
B cells to differentiate from the immature to the transitional 
and from the transitional to the mature B cell stages (Fig. 2,   
B and D). This result was supported by a reduction in absolute 
B cell numbers of 3-83Igi-low cells relative to 3-83Igi and 
CB17 cells in bone marrow chimeras (Table S1).
BCR-low mature B cells have decreased survival in vivo  
but not in vitro
B cell activating factor (BAFF) is a cytokine required for the 
differentiation of transitional into mature B cells and for the 
survival of both B cell types (Schneider et al., 1999; Thompson 
et al., 2000; Harless et al., 2001). In addition, a recent study re-
ported that BAFF-R signaling is dependent on functional tonic 
BCR signaling (Stadanlick et al., 2008). Thus, it was conceiv-
able that a reduced ability to respond to BAFF could explain 
independently of antibody specificity. Moreover, they also sug-
gest that low BCR expression translates into suboptimal tonic 
BCR signaling and that an optimal level of signaling is required 
for B cell development, as previously suggested (Kouskoff 
et al., 2000).
To uncover the full effect of low BCR expression on B 
cell development, mixed bone marrow chimeras were set up 
to compare the ability of 3-83Igi-low and control 3-83Igi B 
cells to develop alongside wild-type (CB17) B cells (Fig. 2 A). 
Cells from each donor were distinguished using the allo-
typic markers IgMa (on 3-83Igi and 3-83Igi-low cells) and 
IgMb (on CB17 cells). In agreement with our previous study   
(Halverson et al., 2004), 3-83Igi B cells developed normally 
in the presence of wild-type cells, maintaining a similar fre-
quency from the immature to the mature B cell stages (Fig. 2, 
B and C). In contrast, the frequency of 3-83Igi-low B cells 
decreased and that of CB17 B cells reciprocally increased as 
Figure 1.  Hypomorphic Ig- expression translates into low BCR levels and impaired B cell development. (A) Scheme of the mb-1 alleles in wild-
type (mb1-wt) and Ig- hypomorphic (mb1-low) mice. Mb1-low mice carry both a conditional (cond.) and a null allele. The white rectangles represent  
mb-1 exon I. Gray rectangles represent mb-1 exons II–V in the genomic (in the wild-type allele) or spliced (in the targeted alleles) forms. White arrows indi-
cate the direction of the coding sequence. The black squares, the black cross, and the black triangles represent the mb-1 poly-A site, an SV40 poly-A se-
quence, and a loxP site, respectively. The hatched rectangles represent a modified EGFP cassette. (B) Western blot analysis of Ig- and -actin in immature 
B cells from IL-7 bone marrow cultures of 3-83Igi and 3-83Igi-low mice. Data are representative of three independent samples. (C) Flow cytometric analy-
sis of surface IgM on bone marrow immature B cells (B220+IgM+IgD–) from 3-83Igi and 3-83Igi-low mice. The shaded histogram represents background 
levels in B220–IgM– cells. (D) Bone marrow (top row) and spleen (bottom three rows) cells from 3-83Igi and 3-83Igi-low mice were analyzed by flow cy-
tometry for surface expression of the indicated markers. Dot plots represent live B220+ lymphocytes. Numbers are percentages of B220+ cells within each 
gate. (E and F) Bar graphs represent mean absolute B cell numbers (±SD; n = 3–6 mice from three to six separate experiments) in the bone marrow (E) and 
spleen (F) of 3-83Igi and 3-83Igi-low mice. The following surface markers were used to discriminate B220+ B cell subsets: immature, IgM+IgD–; transitional 
(bone marrow), IgMhighIgDlow; transitional T1 + T2 (spleen), CD24high; follicular (FO), CD24lowCD21low; and marginal zone (MZ), CD1dhighCD21high.610 Basal BCR signals trigger B cell development | Rowland et al.
this time would indicate a reciprocal change in the frequency 
of 3-83Ig+ B cells. In 3-83Igi:B1-8Hi/3-83ki adoptively trans-
ferred mice, 3-83Igi B cells were recovered on day 41 at a 
frequency that was similar to that of day 0 just before transfer, 
indicating that 3-83Igi and B1-8Hi/3-83ki mature B cells 
had a similar lifespan in vivo (Fig. 3 C). In contrast, the fre-
quency of 3-83Igi-low B cells at days 21 and 41 was slightly 
(1.7-fold at day 41), but statistically significantly, reduced rel-
ative to the initial input. These results indicate a reduced life-
span of the 3-83Igi-low mature B cell population relative to 
the B1-8Hi/3-83ki B cell population in vivo, and may explain 
why the frequency of 3-83Igi-low mature B cells was further 
reduced relative to that of transitional B cells in mixed bone 
marrow chimeras (Fig. 2 D).
Constitutive Bcl-2 expression fails to rescue  
the differentiation of BCR-low immature into transitional  
and mature B cells
The finding that mature 3-83Igi-low B cells had a reduced 
lifespan in vivo suggested that a similar defect in the survival 
of immature B cells might be the cause of reduced transi-
tional B cell numbers. In addition, genetic ablation of the 
BCR has been shown to cause death of mature as well as 
the diminished numbers of mature B cells in 3-83Igi-low 
mice. However, when we compared the survival of 3-83Igi-
low and 3-83Igi spleen B cells in culture with or without 
BAFF, we found that the number of viable cells was similar in 
3-83Igi and 3-83Igi-low cultures regardless of the presence 
of BAFF (Fig. 3 A). These results indicate that 3-83Igi-
low mature B cells had normal intrinsic and BAFF-mediated 
survival in vitro.
In addition to BAFF, BCR expression and signaling have 
been shown to be required for B cell survival in vivo (Lam 
et al., 1997; Meffre and Nussenzweig, 2002; Kraus et al., 2004). 
To test cell survival in vivo, we used a cell-adoptive transfer 
approach to compare the lifespan of 3-83Igi and 3-83Igi-low 
mature B cells to that of B1-8Hi/3-83ki B cells, which express 
normal levels of an innocuous BCR and served as a reference 
population (Fig. 3 B). Spleen B cells from either 3-83Igi 
or 3-83Igi-low mice were mixed in equal numbers with 
B1-8Hi/3-83ki B cells and transferred into B cell–deficient 
mb1/ mice (Pelanda et al., 2002a). The mixed populations 
were analyzed by flow cytometry to measure the frequency 
of B1-8Hi/3-83ki cells in the total B cell population on day 
0 before adoptive transfer, and on days 21 and 41 after transfer. 
Any change in the frequency of B1-8Hi/3-83ki B cells during 
Figure 2.  BCR-low B cells have impaired development in competition with normal B cells. (A) Schematic for the generation of mixed bone mar-
row chimeras. (B) Cells from mixed bone marrow chimeras described in A were analyzed by flow cytometry for the expression of IgMa and IgMb. Numbers 
represent the percentage of IgMa (top, 3-83Igi; bottom, 3-83Igi-low) and IgMb (CB17) cells within the total B220+IgM+ cell population in the bone mar-
row (left) and spleen (right). (C and D) Mean frequencies (±SD; n = 6–10 mice from two separate experiments) of 3-83Igi, CB17, and 3-83Igi-low donor 
cells in mixed 3-83Igi:CB17 (C) and 3-83Igi-low:CB17 (D) bone marrow chimeras. The following surface markers were used to discriminate B cell subsets: 
immature (bone marrow), IgM+IgD–; transitional (bone marrow), IgMhighIgDlow; transitional (spleen), B220+CD24high; and mature (spleen), B220+CD24low. 
N.S., nonsignificant p-values of 0.41–0.43.JEM VOL. 207, March 15, 2010 
Article
611
To test whether differences in Bcl-2 expression and, po-
tentially, in cell survival accounted for reduced transitional and 
mature B cell numbers in 3-83Igi-low mice, mixed bone mar-
row chimeras were set up to assess the ability of 3-83Igi-low B 
cells to differentiate alongside wild-type (CB17) B cells when 
Bcl-2 was constitutively expressed (Fig. 4 B). Bone marrow 
cells from 3-83Igi-low (IgMa) and CB17 (IgMb) donors were 
transduced with bcl-2 to prevent a survival advantage mediated 
by Bcl-2 constitutive expression. The transduction efficiency 
at the time of cell transfer was 40% for CB17 and 30% for 
3-83Igi-low cells (unpublished data), and an equal number of 
cells from each donor were transferred into each recipient. 
Transduced cells were not purified before transfer, thereby 
providing an internal control of nontransduced cells for com-
parison. Thus, the recipient mice displayed four distinct B cell 
populations: CB17 and 3-83Igi-low, which were either trans-
duced or not. As depicted, Bcl-2 levels in transduced 3-83Igi-
low B cells were equivalent to those of transduced CB17 cells 
(Fig. 4 C) and higher than those of intact 3-83Igi-low cells 
(Fig. 4 A). Moreover, retrovirus-encoded Bcl-2 was functional 
as determined by greater recovery of transduced CB17 over 
nontransduced bone marrow and spleen cells (Fig. 4 F and 
Table S1), and by prolonged lifespan of these transduced cells 
in in vitro cell culture (not depicted).
Surprisingly, constitutive Bcl-2 expression did not restore 
the ability of 3-83Igi-low immature B cells to differentiate in 
vivo. As depicted, the frequency (Fig. 4, D and E) of 3-83Igi-low 
B cells relative to that of wild-type cells decreased equally from 
immature to mature B cell stages regardless of Bcl-2 overex-
pression. Furthermore, when analyzing absolute cell num-
bers, an expansion of wild-type (CB17) B cells was observed 
in the transitional and mature B cell populations relative to 
the immature B cell population, and this expansion was am-
plified by Bcl-2 constitutive expression (Fig. 4 F and Table 
S1). In contrast, the transitional and mature 3-83Igi-low B 
cell populations did not expand but displayed a contraction 
relative to their immediate precursors, a contraction that was 
not overcome by Bcl-2 constitutive expression (Fig. 4 F and 
Table S1). Therefore, these data indicate that reduced Bcl-2 
expression and decreased B cell survival are not the primary 
causes for the impaired development of 3-83Igi-low B cells.
Low BCR expression inhibits the differentiation of immature 
B cells in an in vitro system
The observation that 3-83Igi-low B cells were greatly reduced 
in the peripheral lymphoid tissue, even when overexpressing 
the prosurvival protein Bcl-2, suggested that B cells with low 
BCR expression had a specific defect in differentiation. This 
idea agrees with the previous finding that BCR deletion causes 
the “back-differentiation” of immature B cells into cells with 
a pre–B cell–like phenotype (Tze et al., 2005), implying that 
tonic BCR signaling is required to maintain the differentiation 
state of immature B cells.
To further study the role and nature of tonic BCR signals 
in the differentiation of immature B cells, we developed an 
in vitro differentiation system that allows us to follow the 
immature B cells in vivo (Lam et al., 1997; Meffre and 
Nussenzweig, 2002). In light of these facts, we performed a 
flow cytometric characterization of Bcl-2 expression in B 
cells from 3-83Igi and 3-83Igi-low mice because Bcl-2 has 
been well characterized as a potent prosurvival molecule 
and is known to function in this capacity in developing B 
cells (Matsuzaki et al., 1997; Lu et al., 1999). These analyses 
indicated  significantly  reduced  expression  of  Bcl-2  at  all 
stages of 3-83Igi-low B cell development. Immature and 
transitional 3-83Igi-low B cells were particularly affected, 
showing Bcl-2 staining levels close to isotype control (Fig. 4 A 
and Fig. S3).
Figure 3.  Lifespan of mature 3-83Igi-low B cells is normal in vitro 
and slightly reduced in vivo. (A) Spleen B cells from 3-83Igi and  
3-83Igi-low mice were cultured with or without 20 ng/ml of recombinant 
BAFF. Viable cells were enumerated at the indicated times. Data represent 
arithmetic means ± SD from three mice analyzed over two independent 
experiments. (B) Scheme for the adoptive transfer of spleen B cells.  
(C) The frequency of 3-83Ig+ (B1-8H3-83–negative) donor B cells from 
adoptively transferred mice described in B was determined by flow  
cytometry before transfer (on day 0) and on days 21 and 41 after transfer. 
Shown are the arithmetic mean percentages (±SD; n = 4–10 pooled donor 
mice into three recipient mice) of 3-83Igi and 3-83Igi-low donor cells 
within the total CD19+ B cell population. Data are representative of two 
independent experiments.612 Basal BCR signals trigger B cell development | Rowland et al.
phenotype, these cultures represent a population of immature 
B cells and not of pro– or pre–B cells. After the IL-7 culture, 
cells are replated in medium containing BAFF to enhance B 
cell differentiation and survival (Claudio et al., 2002). On sub-
sequent days of BAFF culture, cells are evaluated by flow 
cytometry for the expression of B cell maturation markers. As 
shown in Fig. 5 (A–C), the in vitro differentiation system re-
capitulated the in vivo results, with many 3-83Igi immature 
B cells differentiating to a cell stage that expressed CD21, CD23, 
and IgD by day 2 of BAFF culture, whereas 3-83Igi-low cells 
remained, for the most part, negative for these markers. Similar 
expression of cell-surface markers associated with B cell mat-
uration, as well as to genetically and pharmacologically ma-
nipulate this process. In this system, bone marrow cells from 
3-83Igi and 3-83Igi-low mice are cultured in the presence of 
IL-7 for 3–4 d to enrich for immature B cells. In accordance 
with published studies using 3-83Ig targeted and transgenic 
mice (Melamed et al., 1997; Braun et al., 2000), IL-7 cultures 
of 3-83Igi (and 3-83Igi-low) bone marrow cells generated a 
population of >90% B220+IgM+ cells (Fig. S4 and not de-
picted) that were CD43–/low, CD2+, CD21–/low, CD23–, and 
mostly IgD– (Fig. 5, A and B; and Fig. S4). Based on this 
Figure 4.  Constitutive expression of Bcl-2 fails to rescue the development of 3-83Igi-low B cells. (A) Flow cytometric analysis of endogenous 
Bcl-2 levels in bone marrow and spleen B cells from 3-83Igi and 3-83Igi-low mice. B cell subsets were defined as in Fig. 2 (C and D). Data represent the 
geometric MFIs ± SD from six mice from six separate analyses. The dotted line just above the x-axis represents the average geometric MFI of isotype con-
trol staining. (B) Schematic for the generation of bcl-2 retrogenic mice. (C) Bcl-2 levels in CB17 and 3-83Igi-low transduced (Thy1.1+) bone marrow 
and spleen B cells from bcl-2 retrogenic mice generated as described in B. Data represent the geometric MFIs ± SD of five mice from one experiment.  
(D and E) Frequency of transduced (D) and nontransduced (E) 3-83Igi-low and CB17 donor cells throughout B cell development in bcl-2 retrogenic mice 
described in B. (F) Absolute numbers of B220+ transduced and nontransduced donor-derived B cells within the immature, transitional spleen, and mature 
spleen B cell populations in bcl-2 retrogenic mice described in B–E. B cell subsets were defined as in Fig. 2 (C and D). Data represent the arithmetic means 
± SD of five mice from one experiment. Similar results were obtained in an additional independent experiment with five retrogenic mice.JEM VOL. 207, March 15, 2010 
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delayed kinetics of differentiation, we introduced Bcl-2   
to maintain longer cell survival. We found, however, that 
Bcl-2 constitutive expression maintained the survival of 
undifferentiated immature B cells after IL-7 withdrawal. This 
caused a reduction in the frequency of differentiated cells in 
3-83Igi cultures (Fig. 5 D). Nevertheless, CD21 and CD23 
up-regulation could still be used to follow cell differentiation. 
findings were obtained by comparing in vitro cell differentia-
tion of B1-8Hi/3-83ki and B1-8Hi/3-83ki-low immature B 
cells (Fig. S5).
Despite the presence of BAFF, both 3-83Igi and 3-83Igi-
low B cells displayed a short lifespan in vitro and were not 
present in sufficient numbers to be analyzed past 4 d of culture. 
To understand whether 3-83Igi-low immature B cells had 
Figure 5.  Low BCR expression inhibits differentiation of immature B cells in vitro. (A) Representative kinetics of immature B cell differentiation 
in vitro. Bone marrow cells from 3-83Igi and 3-83Igi-low mice were cultured in the presence of IL-7 for 4 d. After IL-7 culture (day 0), cells were recul-
tured in the presence of BAFF and B220+ cells were analyzed by flow cytometry for expression of CD21, CD23, and IgD at the indicated times. (B) Repre-
sentative flow cytometric analysis of CD21 and CD23 expression in 3-83Igi (top) and 3-83Igi-low (bottom) immature B cells at the indicated time of BAFF 
culture as described in A. Numbers indicate frequencies of live B220+ B cells in quadrant gates. (C) Mean frequency (±SD; n = 3 mice from three indi-
vidual experiments) of CD23+CD21+ B cells at day 2 of BAFF culture as described in B. (D) Representative analysis of CD21 and CD23 expression of bcl-2 
transduced 3-83Igi (top) and 3-83Igi-low (bottom) immature B cells at days 0 and 6 of BAFF culture as described in A. Numbers indicate frequencies of 
live transduced (Thy1.1+) B220+ B cells in quadrant gates. (E) Mean frequency (±SD; n = 2 pooled mice in each of three individual experiments) of CD21+ 
(left) and CD23+CD21+ (right) bcl-2 transduced 3-83Igi and 3-83Igi-low B cells analyzed as in D at day 6 of BAFF culture.614 Basal BCR signals trigger B cell development | Rowland et al.
et al., 1996). The levels of pErk were higher, on average, in 
mature than in transitional and immature B cells of both 
strains. Importantly, however, 3-83Igi-low B cells had de-
creased expression of pErk relative to 3-83Igi at all stages of 
development, as indicated in repeated paired analyses of the 
two strains, and this difference was more significant at the 
immature and transitional than the mature cell stages (Fig. 6 A 
and Fig. S6). Erk has been previously shown to be required 
for pro– to pre–B cell differentiation and for the response of 
pre–B cells to IL-7, suggesting its involvement in pre-BCR 
signaling (Fleming and Paige, 2001; Milne et al., 2008; 
Yasuda et al., 2008). These previous findings and our results 
led us to hypothesize that Erk plays a critical role in mediating 
the differentiation of immature B cells downstream of tonic 
BCR signals.
As Erk is directly activated by the mitogen-activated pro-
tein kinase (MAPK) kinase (MEK), we used the specific MEK 
inhibitor U0126 (Favata et al., 1998; Urosevic et al., 2009) to 
prevent Erk activation in the in vitro B cell differentiation 
assay. As shown in Fig. 6 (B and C), a significantly reduced 
frequency of CD21+CD23+ 3-83Igi B cells was observed in 
cultures in which MEK was inhibited, whereas cell differen-
tiation was unaffected by the p38 MAPK inhibitor SB203580. 
These data, therefore, suggest that the activation of Erk, and 
not that of another MAPK, was important for immature B 
cell differentiation.
In agreement with the bone marrow chimera studies (Fig. 4), 
Bcl-2 overexpression failed to restore normal differentiation 
of 3-83Igi-low immature B cells cultured for up to 6 d, as in-
dicated by a lower frequency of CD21+ and CD21+CD23+ 
cells relative to bcl-2–transduced 3-83Igi cultures (Fig. 5, D 
and E). However, the in vitro defect was not absolute and a 
small fraction of 3-83Igi-low immature B cells (20%) dis-
played markers of differentiation, as shown by up-regulation 
of CD21 (Fig. 5, D and E). These analyses indicate that opti-
mal BCR expression and signaling are needed to promote 
development beyond the immature B cell stage in vitro as 
well as in vivo. However, some differentiation can occur in 
cells expressing suboptimal levels of BCR when cell survival 
is artificially prolonged, at least in vitro.
Constitutive activation of Ras restores the differentiation  
of 3-83Igi-low immature B cells in vitro and in vivo
It is well known that Erk is a major downstream effector of 
the BCR signaling pathway. To determine whether Erk me-
diates tonic BCR signals that are involved in immature B cell 
differentiation, we compared the levels of phosphorylated 
Erk (pErk) in 3-83Igi and 3-83Igi-low B cells by flow cyto-
metric analyses. In untreated B cells, pErk was only weakly 
and inconsistently detected (unpublished data). Therefore, 
we evaluated pErk in B cells treated with sodium pervanadate 
to amplify the low BCR signal of resting cells (Wienands 
Figure 6.  Inhibition of Erk activity impairs the in vitro differentiation of normal immature B cells. (A) Bone marrow (immature) and spleen 
(transitional and mature) B cells from 3-83Igi and 3-83Igi-low mice were treated with pervanadate and analyzed by intracellular flow cytometry for ex-
pression of pErk. B cell subsets were defined as in Fig. 2 (C and D). Data represent the geometric MFIs from four mice and four individual experiments. 
Matching filled and open symbols represent mice that were analyzed at the same time (paired samples). The short black bars indicate average MFIs, and 
the dashed line just above the x-axis represents the average geometric MFI of isotype control staining. (B) Representative flow cytometric analysis of 
CD21 and CD23 expression in 3-83Igi immature B cells cultured as described in Fig. 5 A, with the exception that cells were treated with 10 µM U0126 
(MEK inhibitor) in 0.04% DMSO, 10 µM SB203580 (p38 inhibitor) in 0.3% DMSO, or respective amounts of DMSO only during BAFF culture. Cells were 
analyzed at days 0 and 2 of BAFF culture. Numbers indicate frequencies of live B220+ B cells in quadrant gates. (C) Mean frequency (±SD; n = 3 mice from 
three individual experiments) of CD23+CD21+ 3-83Igi B cells at day 2 of BAFF culture as described in B.JEM VOL. 207, March 15, 2010 
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Our analyses clearly show the presence of a large fraction of 
CD23+CD21+ (and IgD+; not depicted) 3-83Igi-low cells 
expressing constitutively active N-RasD12 after IL-7 with-
drawal, whereas CD23+CD21+ cells were not observed in 
control cultures transduced with gfp only (Fig. 7, A and B). 
Similar findings were obtained after N-RasD12 transduction 
of B1-8Hi/3-83ki-low immature B cells (unpublished data). 
Moreover, N-RasD12 transduction further improved the 
differentiation of BCR-normal 3-83Igi B cells, generating 
To further test a role for Erk in immature B cell differen-
tiation, we promoted Erk activity by using a constitutively 
active form of human N-Ras that carries a G to D single 
amino acid substitution at position 12 (N-RasD12; Bos, 1989; 
Scheffzek et al., 1997). Ras activation leads to the activation 
of MEK via Raf and, therefore, to the activation of Erk (Kolch, 
2000). Immature B cells from 3-83Igi-low mice were trans-
duced in vitro with retroviruses encoding either N-RasD12 or 
GFP-only control and assayed for in vitro B cell differentiation. 
Figure 7.  Active Ras restores the differentiation of 3-83Igi-low immature B cells in vitro and in vivo. (A) Representative analysis of CD21 and 
CD23 expression in either gfp control (top) or N-rasD12 (bottom) transduced 3-83Igi-low immature B cells at days 0 and 2 of BAFF culture as described in 
Fig. 5 A, and in the presence or absence of MAPK pharmacological inhibitors as described in Fig. 6 B. 0.3% DMSO was included as solvent control. Num-
bers indicate frequencies of live transduced B220+ B cells in quadrant gates. (B) Mean frequency (±SD; n = 2 pooled mice in each of three individual ex-
periments) of CD23+CD21+ transduced B cells at day 2 of BAFF culture as described in A. Graphs represent data from treatment with 10 µM U0126 in 
0.04% DMSO (top) or 10 µM SB203580 in 0.3% DMSO (bottom) and appropriate DMSO-only controls. (C) Schematic for the generation of N-rasD12 and 
gfp control retrogenic mice. (D) Representative flow cytometric analysis of spleen cells from N-rasD12 and gfp control retrogenic mice described in C. 
Expression of the indicated markers on CB17 (from gfp retrogenic mice; top), N-rasD12 transduced 3-83Igi-low (middle), and gfp transduced 3-83Igi-low 
(bottom) cells is shown. Donor cells were gated as B220+IgMb+ for CB17 and B220+IgMa+GFP+ for 3-83Igi-low. Numbers are frequencies of cells in the 
indicated gates, and data are representative of six retrogenic mice from one experiment. Similar results were obtained in an additional independent ex-
periment with three to four retrogenic mice per group. (E) Mean frequency of CD23–/lowCD24high (T1), CD23highCD24high (T2), CD21+CD23+ (T2/mature), and 
IgDhighIgMlow (T2/mature) donor spleen cells in the retrogenic mice described in C and D. CB17 (from gfp retrogenic mice), N-rasD12 transduced 3-83Igi-low, 
and gfp transduced 3-83Igi-low cells are shown. Data represent arithmetic means ± SD of six retrogenic mice from one experiment.616 Basal BCR signals trigger B cell development | Rowland et al.
B cells. Previous studies have shown that BCR deletion and, 
therefore, the total ablation of tonic BCR signals results in the 
back-differentiation of immature B cells into pre–B-like cells, 
indicating that the maintenance of the immature B cell stage 
requires active tonic BCR signaling (Tze et al., 2005). Our 
study extends those findings by showing that low BCR ex-
pression leads to suboptimal tonic BCR signals resulting in 
impaired differentiation of nonautoreactive immature B cells 
into transitional and mature B cells. In our studies, we con-
trolled the specificity of B cells through the use of targeted H 
and L transgenes (knockin). Low BCR expression had similar 
effects on B cell development whether the cells expressed the 
nonautoreactive 3-83H3-83 or the B1-8H3-83 antibody 
chain combinations, indicating that the phenotype was inde-
pendent of the B cell specificity. Moreover, similar defects in 
B cell generation were observed in BCR-low mice with a 
normal polyclonal B cell repertoire. It is conceivable that sub-
optimal tonic BCR signals impair allelic exclusion and, con-
sequently, activate receptor editing. Under this hypothesis, 
BCR-low immature B cells would be delayed in differentia-
tion relative to B cells expressing normal BCR levels (Casellas 
et al., 2001). However, our analyses discount this possibility, 
as 94–95% of peripheral IgM+ B cells in both 3-83Igi-low and 
B1-8Hi/3-83ki-low mice expressed the original specificity 
(unpublished data). In our experiments, we used mb-1 hemi-
zygous mice in which immature B cells expressed 18% of the 
normal IgM levels. In additional experiments, we analyzed 
3-83Igi mice carrying two conditional mb-1 alleles (3-83Igi-int 
mice) that displayed a less severe hypomorphism characterized 
by IgM levels that were 50–70% of normal, and follicular B 
cell numbers that were intermediate between those of 3-83Igi 
and 3-83Igi-low mice (Fig. S7, A and B). We found, how-
ever, that immature B cells from 3-83Igi-int mice were still 
severely  affected  in  differentiation  in  vitro,  although  to  a 
lower extent than in 3-83Igi-low mice (Fig. S7 C). It is worth 
noting that IgM expression is widely distributed (over a 2-log 
range) in immature B cells and that 40% of 3-83Igi-low im-
mature B cells displayed IgM levels within the low end of ex-
pression of 3-83Igi immature B cells. This overlap in IgM 
expression might explain why a small fraction of BCR-low 
immature B cells was capable of further differentiation but 
also supports the idea that the IgMlow fraction of BCR-normal 
immature B cells may be impaired and/or delayed in differen-
tiation, as previously proposed (Melamed et al., 1998). Over-
all, these findings suggest that in immature B cells, optimal 
tonic BCR signals depend on proper levels of IgM expres-
sion, and indicate that a threshold level of BCR expression is 
necessary to trigger a tonic BCR signal able to initiate the dif-
ferentiation of immature B cells into transitional B cells.
Tonic BCR signals have been previously shown to be 
important for the maintenance of immature and mature B cell 
survival in vivo (Lam et al., 1997; Meffre and Nussenzweig, 
2002; Kraus et al., 2004). However, enforced cell survival by 
increased Bcl-2 expression did not ameliorate the differentia-
tion of 3-83Igi-low B cells either in vitro or in vivo. Although 
we cannot exclude that constitutive expression of a different 
more CD21+CD23+ B cells after 2 d of BAFF culture (un-
published data). These results demonstrate that active N-Ras 
aids the differentiation of immature into transitional B cells 
and complements the differentiation defect of BCR-low 
immature B cells in vitro. To determine if N-RasD12 restored 
the differentiation of 3-83Igi-low and B1-8Hi/3-83ki-low 
B cells by specifically activating the Erk pathway, we used the 
MEK inhibitor U0126 to prevent Erk activation in trans-
duced cells. We found that the differentiation of BCR-low 
immature into transitional B cells mediated by constitutively 
active N-Ras in vitro was inhibited by U0126 but not by the 
p38 inhibitor, strongly suggesting that Ras promoted imma-
ture B cell differentiation via Erk in vitro (Fig. 7, A and B; 
and not depicted).
To examine the ability of Ras to promote B cell develop-
ment in vivo, we generated retrogenic mice by transduc-
ing 3-83Igi-low bone marrow cells with either gfp control or 
N-rasD12–encoding retroviruses. As done with bcl-2 retro-
genic mice, we chose to assess the differentiation capacity of 
3-83Igi-low B cells along that of wild-type CB17 B cells   
(Fig. 7 C). Chimeric mice were analyzed at 3 wk after transfer 
to limit tumor development caused by the expression of the 
constitutively active Ras oncogene (Braun et al., 2004; Chan 
et al., 2004). At this time, wild-type (CB17) B cells had pro-
gressed to the transitional T1 (CD24hiCD21–/lowCD23–/low) 
and T2 (CD24hiCD21hiCD23hi) stages, whereas fully mature 
CD24low B cells had not yet developed (Fig. 7 D). Because of 
the competitive advantage of N-rasD12–transduced cells, only 
a small frequency of CB17 B cells was detected in N-rasD12 
retrogenic mice (unpublished data). Nevertheless, the majority 
of the CB17 spleen B cell population was composed of T2 
cells in both retrogenic mice groups (Fig. 7, D and E; and 
not depicted), whereas B cells of the control gfp transduced 
3-83Igi-low population were mostly at the T1 cell stage of mat-
uration (Fig. 7, D and E). In contrast to control 3-83Igi-low 
cells, the population of N-rasD12–transduced 3-83Igi-low 
B cells was composed mainly of T2 cells in a similar propor-
tion to that of the wild-type B cell population (Fig. 7, D and E). 
As with CB17 cells, only small numbers of nontransduced 
(GFP–) 3-83Igi-low B cells were detected in N-rasD12 retro-
genic mice because of the competitive advantage mediated 
by this oncogene in transduced cells. However, when de-
tected, nontransduced (GFP–) 3-83Igi-low B cells were mostly 
found at the T1 stage (unpublished data), indicating that the 
differentiation mediated by N-RasD12 in transduced cells is 
a cell-autonomous process. Therefore, in accordance with 
the in vitro studies, constitutive expression of active N-Ras 
restored the ability of 3-83Igi-low B cells to develop to the 
T2 cell stage in vivo. In fact, expression of active N-Ras 
permitted 3-83Igi-low B cells to differentiate comparably 
to wild-type B cells within the same individual mouse.
DISCUSSION
In this study, we provide evidence that tonic BCR signaling 
propagates via the Erk pathway to specifically mediate the 
development of immature B cells into transitional and mature JEM VOL. 207, March 15, 2010 
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immature and transitional B cells expressing suboptimal levels 
of BCR had reduced amounts of pErk, suggesting that tonic 
BCR signals are proportional to Erk phosphorylation. The pErk 
analysis was performed on cells treated with pervanadate, 
which  is  known  to  inhibit  tyrosine  phosphatases,  thereby 
amplifying the effect of kinases. Thus, our data suggest that 
BCR-low–developing B cells have reduced expression and/or 
activity of kinases upstream of Erk, which has not been pres-
ently determined. Recent studies have shown that the com-
bined deletion of Erk1 and Erk2 results in a complete block 
in the differentiation of pro– to pre–B cells, and indicated 
that the Erk pathway propagates pre-BCR signals required 
for pre–B cell development (Yasuda et al., 2008). In our sys-
tem, we used Ig-targeted mice with prerearranged H and L 
chain genes that allowed the progenitor B cells to advance to 
the immature B cell stage without the requirement for pre-
BCR signaling and Ig gene recombination. Thus, this system 
allowed us to look at the role of Erk in the progression of im-
mature into transitional and mature B cells. Our data strongly 
suggest that activation of Erk is required for this differentia-
tion step. Erk requirement is indicated by the following find-
ings. Only a few 3-83Igi-low B cells reach the mature B cell 
stage, and these cells display high levels of pErk that are simi-
lar to those of mature 3-83Igi B cells, suggesting a role for 
Erk in the positive selection process of immature B cells. Ad-
ditionally, reduced differentiation of 3-83Igi normal imma-
ture B cells was observed when Erk activation was prevented 
after MEK inhibition by U0126. Under similar conditions, a 
MAPK p38 inhibitor did not alter the differentiation of nor-
mal immature B cells, indicating that not all MAPKs are 
equivalent in mediating immature B cell differentiation. Fur-
thermore, differentiation of BCR-low immature B cells was 
restored by expression of a constitutively active form of 
N-Ras, a kinase that leads to the activation of Erk. Impor-
tantly, the differentiating function of N-Ras appeared to be 
mediated via Erk, as it was inhibited by U0126 in vitro. Al-
though the inhibitor U0126 has been demonstrated to be 
particularly specific to MEK, it cannot be excluded that this 
inhibitor may target another molecule involved in B cell dif-
ferentiation. Similarly, Ras is known to activate other down-
stream molecular pathways, in addition to Erk, that also may 
be involved in B cell differentiation. However, the use of these 
complementary approaches strengthens our conclusion that 
active Erk mediates the differentiation of immature into tran-
sitional B cells via a Ras-dependent pathway. An alternative 
but less likely explanation is that N-RasD12 activates a differ-
ent downstream mediator of cell differentiation that happens 
to be an additional target of U0126. The inactivation of Ras 
has been previously shown to inhibit B cell development 
at the pro– to pre–B cell transition (Iritani et al., 1997), the 
same stage as shown for Erk1/2 deletion (Yasuda et al., 2008). 
Furthermore, a constitutively active H-RasV12 was shown 
to cause the progression of Rag1-deficient pro–B cells to cells 
that, despite the absence of Ig expression, displayed the mature 
markers CD21 and CD23 (Shaw et al., 1999). Overall, these 
reports suggest that active Ras can propagate differentiation 
prosurvival molecule may restore the differentiation of BCR-
low B cells, our data argue against this possibility. In fact, al-
though both the bcl-2 and N-rasD12 genes promoted cell 
survival as indicated by a longer lifespan in vitro (unpublished 
data), bcl-2–transduced B cells remained mostly at the CD21–
CD23– immature stage. In contrast, N-rasD12–transduced B 
cells progressed to the transitional cell stage characterized by 
CD21 and CD23 expression. Therefore, although cell sur-
vival is a prerequisite for cell differentiation, reduced cell sur-
vival was not the primary cause of the impaired differentiation 
of BCR-low immature B cells. Our data strongly suggest that 
tonic BCR signals propagated via Erk, likely through Ras, 
are specifically required for the export of immature B cells 
from the bone marrow and their differentiation into transi-
tional B cells.
In addition to a defect during bone marrow B cell devel-
opment, BCR-low mice were unable to accumulate normal 
numbers of mature B cells in the spleen. This may be caused 
by the fact that BCR-low mature B cells had a slightly re-
duced lifespan in vivo relative to BCR-normal B cells. Thus, 
our findings agree with previous reports indicating that tonic 
BCR signals contribute to the survival of mature B cells (Lam 
et al., 1997; Meffre and Nussenzweig, 2002; Kraus et al., 
2004). In addition to this previously recognized function, our 
data suggest that tonic BCR signals are also required for the 
differentiation of transitional B cells into mature B cells. Evi-
dence for this novel role comes from the analysis of B cell 
development in bcl-2 retrogenic mice. Specifically, 3-83Igi-
low transitional B cells had impaired differentiation into ma-
ture B cells, even when provided with the prosurvival gene 
bcl-2, as demonstrated by a decrease in the frequency and a 
lack of expansion in numbers of B cells from the transitional 
to mature B cell populations. These results, therefore, indicate 
that in peripheral B cell populations, tonic BCR signals are 
required for both the differentiation of transitional into ma-
ture B cells and the maintenance of the mature B cell pool.
The cytokine BAFF has been shown to contribute to the 
development and survival of transitional T2 and mature B cells 
(Gross et al., 2001; Sasaki et al., 2004). Both ligand-dependent 
and -independent BCR signals have been recently reported 
to generate the NF-B p100 subunit that is required for func-
tional BAFF-R signaling in response to BAFF (Stadanlick 
et al., 2008). Consequently, it is conceivable that BCR-low 
immature B cells are impaired in differentiation because they 
are unable to generate p100 and respond to BAFF. This sce-
nario, however, is unlikely for the following two reasons. 
First, normal immature B cells differentiate to T1 B cells re-
gardless of BAFF or BAFF-R signaling (Gross et al., 2001; 
Sasaki et al., 2004), whereas we show that BCR-low imma-
ture B cells did not efficiently progress to the T1 stage. Sec-
ond, 3-83Igi-low mature B cells had a normal response to 
BAFF in vitro, again suggesting that the reduced expression of 
BCR in these cells did not impair optimal p100 production. 
Nevertheless, this issue requires further clarification.
The nature of tonic BCR signaling and how it differs 
from that mediated by ligand is still unclear. We found that 618 Basal BCR signals trigger B cell development | Rowland et al.
Conversely, it may lead to positive selection of immature B 
cells in the absence of proper tonic BCR signaling, a process 
that could involve autoreactive immature B cells and lead to 
the development of autoantibodies.
MATERIALS AND METHODS
Mice. The 3-83Igi (Igh3-83/3-83Igk3-83/3-83H-2d/d; Braun et al., 2000; Halverson 
et al., 2004), B1-8Hi/3-83ki (IghB1-8/+Igk3-83/+; Pelanda et al., 1997), mb-1 
null (mb-1/; Pelanda et al., 2002a), and mb-1 conditional (mb-1mb-1-mEGFPinv;   
Pelanda et al., 2002b) mice have been previously described. The mb1-low   
(mb-1/mb-1-mEGFPinv), 3-83Igi-low (Igh3-83/3-83Igk3-83/3-83H-2d/dmb-1/mb-1-mEGFPinv),   
3-83Igi-int (Igh3-83/3-83Igk3-83/3-83H-2d/dmb-1mb-1-mEGFPinv/mb-1-mEGFPinv), B1-
8Hi/3-83ki-low (IghB1-8/+Igk3-83/+mb-1/mb-1-mEGFPinv), and 3-83Igi-mb1/ 
(Igh3-83/3-83Igk3-83/3-83H-2d/dmb-1/)  mice  were  generated  for  this  study. 
CB17 mice were initially purchased from the Jackson Laboratory. All mice 
were on a BALB/c genetic background and were bred and maintained in 
specific pathogen–free rooms at the Biological Resource Center at National 
Jewish Health (NJH). All animal experiments were approved by the NJH 
Institutional Animal Care and Use Committee.
Retroviral  constructs  and  production  of  retroviral  particles. The 
  pMSCV-Flag-Bcl2-IRES-Thy1.1 (a gift of A. Desbien and P. Marrack, NJH, 
Denver, CO; Desbien et al., 2009), pMSCV-IRES-GFP (Van Parijs et al., 
1999), and pMSCV-GFP-IRES-hN-RasG12D (a gift from J. DeGregori, 
University of Colorado Denver, Denver, CO) retroviral vectors encode 
replication-deficient viruses. The pCL-Eco vector is an ecotropic helper vector 
(Naviaux et al., 1996). Retroviruses were produced in Phoenix cells (Swift 
et al., 2001) using Lipofectamine 2000 Transfection Reagent (Invitrogen) 
optimized according to the manufacturer’s instructions. At 48 and 72 h after 
transfection, viral supernatants were collected and filtered through 0.45-µm 
filters, flash frozen in liquid nitrogen, and stored at 80°C.
Flow  cytometry  and  antibodies. Single-cell suspensions were stained 
with fluorescent monoclonal antibodies against B220 (RA3-6B2), CD21 
(7G6),  CD23  (B3B4),  CD24  (M1/69),  IgMa  (DS-1),  IgMb  (AF6-78), 
CD90.1/Thy1.1 (OX-7), and CD1d (1B1) purchased from either BD or 
eBioscience. Antibodies against IgM (R33-24.12; Leptin et al., 1984), IgD 
(1.3-5; Roes et al., 1995), CD19 (1D3; Krop et al., 1996), B1-8H (Ac-146; 
Reth et al., 1979), and Bcl-2 (3F11; a gift of P. Marrack;  Reed et al., 1987) 
were generated in house. Biotinylated antibodies were revealed with fluoro-
chrome-conjugated streptavidin (Invitrogen). Bcl-2 (and isotype control) 
staining was performed in saponin-treated cells as previously described (Veis 
et al., 1993). 1.25 µg/ml propidium iodide (PI) was added to some samples 
to exclude dead cells. Analysis was performed on live B220+ or CD19+ lym-
phocytes based on incorporation of PI and/or forward and side scatter using 
the Cyan analyzer (Dako) and FlowJo software (Tree Star, Inc.).
pErk flow cytometric analysis. Freshly isolated single-cell suspensions 
were rested on ice for 1 h in HBSS with Ca2+ and Mg2+ (Cellgro) containing 
1% FBS. Cells were treated with 60 µM sodium pervanadate for 5 min at 
37°C, fixed in 2% paraformaldehyde, and permeabilized in 90% methanol. 
Cells were washed with PBS and stained with 1 µg/ml anti-pErk Thr202/
Tyr204 (197G2; Cell Signaling Technology) or isotype control antibodies 
for 45 min at room temperature. Primary antibodies were revealed with a 
fluorescent anti–rabbit IgG antibody (SouthernBiotech). Sodium pervana-
date was prepared by incubating a mixture of 900 µl water, 100 µl of 200 mM 
Na3VO4, and 330 µl of 30% H2O2 for 5 min at room temperature to yield a 
6-mM solution, and was used at a final dilution of 1:100.
Generation of bone marrow chimera and retrogenic mice. Recipient 
mice were irradiated as previously described (Velez et al., 2007). Donor 
bone marrow cells were mixed at the ratios indicated in the figures, and a 
total of 1–2 × 106 cells in 100 µl PBS were injected in a tail vein of each re-
cipient. When generating retrogenic mice, donor mice were injected i.p. 
with 3.75 mg 5-FU 4 d before bone marrow harvest. Cells were cultured 
signals in B cells, and also support our argument that both 
Ras and Erk activities are necessary during B cell develop-
ment. It is relevant to note that Ras and Erk activities have also 
been implicated in thymocyte development. A recent study 
has elegantly shown that positive selection of thymocytes in-
volves a specific compartmentalization of Ras/MAPK signaling 
at the Golgi instead of the plasma membrane (Daniels et al., 
2006). Thus, in the future it will also be important to define 
whether  a  similar  compartmentalization  of  these  signaling 
molecules occurs during positive and negative selection of 
immature B cells.
We were unable to find mature, CD24low B cells in   
N-rasD12 retrogenic mice at 3 wk after the inception of chi-
merism. Unfortunately, the rapid tumorigenesis and death me-
diated by N-rasD12 prevented us from analyzing most mice 
at later time points. Nevertheless, we believe that the absence 
of mature B cells was caused by the short-term hematopoietic 
reconstitution and does not indicate that constitutively active 
Ras cannot mediate the development of mature B cells. This 
view is supported by the fact that even CB17 intact B cells 
did not reach the CD24low mature B cell stage in the same mice. 
Moreover, two N-rasD12 retrogenic mice that survived for 
4 wk had 3-83Igi-low B cells at the mature, CD24low stage 
(unpublished data), agreeing with the idea that active Ras 
mediates the differentiation of immature B cells all the way 
to the mature cell stage of development. Constitutively active 
forms of Ras are known oncogenes that prolong the survival 
of transformed cells. In line with this knowledge, we observed 
that B cells expressing N-rasD12 survived longer in vitro 
(unpublished data). Nevertheless, N-RasD12 had a peculiar 
capacity to push BCR-low immature B cells to differentiate. 
This role appeared to be independent of the prosurvival func-
tion of Ras, as suggested by the fact that BCR-low immature 
B cell differentiation was not promoted by increased cell sur-
vival after constitutive expression of Bcl-2. Along this line, 
the tumors that developed in N-rasD12 retrogenic mice ap-
peared to be of myeloid and not lymphoid origin (unpublished 
data), supporting the idea that Ras promotes differentiation, 
and not merely survival and proliferation, of B cells. Thus, 
our observations, together with those previously published, 
provide compelling evidence to support a model in which 
sufficient BCR levels trigger tonic BCR signals that activate 
Erk in a Ras-dependent manner to promote differentiation 
of nonautoreactive immature B cells into transitional and ma-
ture B cells.
In both mice and humans, the bone marrow immature B 
cell stage is an important checkpoint at which most autoreac-
tive immature B cells are eliminated, whereas nonautoreactive 
B cells migrate to the spleen to generate the naive B cell rep-
ertoire (Grandien et al., 1994; Wardemann et al., 2003). Our 
study suggests that this checkpoint is a positive selection pro-
cess regulated by proper activation of Ras and Erk. If so, modi-
fications of the Ras and Erk signaling pathways would be 
expected to affect the peripheral B cell pool. In one scenario, 
altered Ras/Erk activation may lead to decreased periph-
eral B cell generation and consequent immunodeficiency. JEM VOL. 207, March 15, 2010 
Article
619
variance (using Welch’s correction when appropriate). P < 0.05 was consid-
ered significant. Data are represented as means ± SD.
Online supplemental material. Fig. S1 describes the generation of transi-
tional and mature B cells in B1-8Hi/3-83ki-low mice. Fig. S2 describes the 
generation of mature B cells in BCR-low mice with a normal Ig repertoire. 
Fig. S3 shows representative flow cytometric analysis of Bcl-2 expression in 
3-83Igi and 3-83Igi-low bone marrow and spleen B cells. Fig. S4 shows the 
phenotypic characterization of B cells in IL-7 bone marrow cultures. Fig. S5 
describes the differentiation of B1-8Hi/3-83ki-low immature B cells in vitro. 
Fig. S6 shows representative flow cytometric analysis of pErk expression in 
3-83Igi and 3-83Igi-low bone marrow and spleen B cells. Fig. S7 describes 
the generation of mature B cells in 3-83Igi-int mice, and shows the in vitro 
differentiation of 3-83Igi-int immature B cells. Table S1 displays the abso-
lute bone marrow and spleen cell numbers recovered from bone marrow 
chimera mice. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20091673/DC1.
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